Abbott Becomes Third US TAVR Competitor With Portico Approval

Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.

Abbott's Portico TAVR with FlexNav Delivery System • Source: Abbott

Abbott will take on Edwards Lifesciences and Medtronic in the US transcatheter aortic valve replacement (TAVR) market with the Portico self-expanding valve with the FlexNav delivery system.

The US Food and Drug Administration approved Portico with FlexNav to treat people with symptomatic, severe aortic stenosis whose...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation